Fish products

Latest Research Evaluating VASCEPA® (Icosapent Ethyl) Mechanisms of Action Presented at European Atherosclerosis Society (EAS) Congress 2020

Retrieved on: 
Monday, October 5, 2020
Organic compounds, Amarin Corporation, Fish products, RTT, Chemistry, Ethyl eicosapentaenoic acid, Chemical compounds, Niacin, Cardiovascular disease

The new data presented at EAS Congress 2020 helps to further understand the unique ways by which VASCEPA lowers persistent cardiovascular risk and helps to address the global impact of cardiovascular disease.

Key Points: 
  • The new data presented at EAS Congress 2020 helps to further understand the unique ways by which VASCEPA lowers persistent cardiovascular risk and helps to address the global impact of cardiovascular disease.
  • Amarins lead product, VASCEPA (icosapent ethyl), is available by prescription in the United States, Canada, Lebanon and the United Arab Emirates.
  • VASCEPA is contraindicated in patients with known hypersensitivity (e.g., anaphylactic reaction) to VASCEPA or any of its components.
  • Key clinical effects of VASCEPA on major adverse cardiovascular events are included in the Clinical Studies section of the prescribing information for VASCEPA as set forth below:

Fish Without Fish; Making the Best Plant-Based Fish Textures Using Meatless Products, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Wednesday, September 23, 2020
Articles, Intentional living, Ethics, Philosophical theories, Ethical theories, Sustainable food system, Diets, Veganism, Vegetarianism, Fish products

The featured speakers will provide insights on how the fish and fish substitute market is developing and what the latest trends and challenges are.

Key Points: 
  • The featured speakers will provide insights on how the fish and fish substitute market is developing and what the latest trends and challenges are.
  • This webinar is the second in a series of four, offered by Meatless , that handles specific techniques to make palatable vegan/vegetarian products.
  • In this webinar, panellists will demonstrate the latest processing methods to make vegetarian or vegan processed fish products.
  • For more information or to register for this event, visit Fish Without Fish; Making the Best Plant-Based Fish Textures Using Meatless Products.

Amarin Provides Update Following Ruling in VASCEPA® ANDA Patent Litigation

Retrieved on: 
Thursday, September 3, 2020
Amarin Corporation, Fish products, Ethyl eicosapentaenoic acid, Chemistry, Physical sciences

We are extremely disappointed with todays ruling and plan to vigorously pursue available remedies, said John Thero, president and chief executive officer, Amarin.

Key Points: 
  • We are extremely disappointed with todays ruling and plan to vigorously pursue available remedies, said John Thero, president and chief executive officer, Amarin.
  • Amarin anticipates that generics companies, when they launch in the United States, are likely to have limited supply capacity for VASCEPA.
  • Based on this assumption and given the need for greater awareness of VASCEPA by healthcare professionals and at-risk patients, Amarin intends to continue current promotion levels of VASCEPA in the United States.
  • Geographies outside the United States in which VASCEPA is sold and under regulatory review are not subject to this litigation and judgment.

Amarin Supports Latest Clinical Research Evaluating VASCEPA® (Icosapent Ethyl) in Patients with Persistent Cardiovascular Risk Presented at ESC Congress 2020, the Annual Meeting of the European Society of Cardiology

Retrieved on: 
Tuesday, September 1, 2020
Clinical research, Health, Medicine, Articles, Fish products, Clinical trials, Biochemistry, Ethyl eicosapentaenoic acid, Polyolefins, Statin, Major adverse cardiovascular events, Clinical endpoint

The prespecified primary endpoint was a comparison of change in LAP volume at 18 months between icosapent ethyl and placebo.

Key Points: 
  • The prespecified primary endpoint was a comparison of change in LAP volume at 18 months between icosapent ethyl and placebo.
  • The only secondary endpoint which did not achieve a significant difference between groups in multivariable modeling was dense calcium (p=0.053).
  • VASCEPA is the first and only agent studied on top of statin therapy reported to exhibit coronary plaque regression in hypertriglyceridemic patients.
  • Key clinical effects of VASCEPA on major adverse cardiovascular events are included in the Clinical Studies section of the prescribing information for VASCEPA as set forth below:

VASCEPA® (Icosapent Ethyl) Reported to Significantly Reduce Coronary Plaque in EVAPORATE Study Final Results Presented at ESC Congress 2020

Retrieved on: 
Saturday, August 29, 2020
RTT, Fish products, Organic compounds, Cardiovascular disease, Ethyl eicosapentaenoic acid, Chemistry, Branches of biology

As referenced below, these final results can be found in the concurrent publication in European Heart Journal.

Key Points: 
  • As referenced below, these final results can be found in the concurrent publication in European Heart Journal.
  • The coronary plaque reduction shown in EVAPORATE is consistent with the benefits of icosapent ethyl in cardiovascular event outcomes shown in REDUCE-IT, a separate study.
  • The EVAPORATE study results potentially shed further light on how VASCEPA works to lower residual cardiovascular risk.
  • More study is needed to demonstrate the effects of VASCEPA on coronary plaque to determine the relationship of such effects, if any, on cardiovascular risk reduction.

Matinas BioPharma Completes Enrollment of ENHANCE-IT Study of MAT9001 Against Vascepa®

Retrieved on: 
Thursday, August 27, 2020
Drugs, Organic compounds, Chemistry, Fish products, Biochemistry, Ethyl eicosapentaenoic acid, Polyolefins, Treatment of bipolar disorder, Crossover study, Medroxyprogesterone acetate, Amarin Corporation

Successful completion of ENHANCE-IT enrollment is a key milestone for Matinas, and this study will provide important data for both MAT9001 and Vascepa.

Key Points: 
  • Successful completion of ENHANCE-IT enrollment is a key milestone for Matinas, and this study will provide important data for both MAT9001 and Vascepa.
  • ENHANCE-IT is an open-label, randomized, 28-day crossover study assessing the pharmacodynamic effects of MAT9001 vs. Vascepa.
  • MAT9001 and Vascepa are each administered as 2g twice daily with food in accordance with currently approved Vascepa labeling.
  • Matinas BioPharma is a clinical-stage biopharmaceutical company focused on development of its lead product candidate, MAT9001, for the treatment of cardiovascular and metabolic conditions.

Amarin Supports Investigator-Initiated Trial at Kaiser Permanente in the U.S. to Study the Effects of VASCEPA® (icosapent ethyl) in Reducing Viral Upper Respiratory Infections, Including COVID-19 and Flu, and the Clinical Severity of Such Infections

Retrieved on: 
Friday, August 7, 2020
Amarin Corporation, Fish products, Ethyl eicosapentaenoic acid, Chemistry, Physical sciences

For more information about Amarins COVID-19 research, please visit the COVID-19 Related Materials section on Amarins publications page at https://investor.amarincorp.com/publications .

Key Points: 
  • For more information about Amarins COVID-19 research, please visit the COVID-19 Related Materials section on Amarins publications page at https://investor.amarincorp.com/publications .
  • Amarin Corporation plc is a rapidly growing, innovative pharmaceutical company focused on developing and commercializing therapeutics to cost-effectively improve cardiovascular health.
  • Amarins lead product, VASCEPA (icosapent ethyl), is available by prescription in the United States, Canada, Lebanon and the United Arab Emirates.
  • Key clinical effects of VASCEPA on major adverse cardiovascular events are included in the Clinical Studies section of the prescribing information for VASCEPA, as set forth below:

Amarin Announces Plans to Maximize Blockbuster Potential of VASCEPA® (icosapent ethyl) in Europe

Retrieved on: 
Tuesday, August 4, 2020
Companies, Amarin Corporation, Fish products, Ethyl eicosapentaenoic acid, Blockbuster LLC, Chemistry, Economy of the United States

Based on that analysis, we determined that a commercialization team within Amarin and dedicated to VASCEPA is the best choice to maximize the blockbuster potential of the drug in Europe.

Key Points: 
  • Based on that analysis, we determined that a commercialization team within Amarin and dedicated to VASCEPA is the best choice to maximize the blockbuster potential of the drug in Europe.
  • We look forward to advancing VASCEPA through the regulatory process and maximizing the blockbuster potential of VASCEPA in Europe to help millions of patients in need.
  • Over the past year, Amarin has made considerable progress laying the foundation for a successful commercial launch in Europe.
  • To enable Amarin to deliver on its vision in Europe, the company announces its recent hiring of Karim Mikhail as senior vice president, commercial head Europe.

Amarin Announces Plans to Maximize Blockbuster Potential of VASCEPA® (icosapent ethyl) in Europe

Retrieved on: 
Tuesday, August 4, 2020
Companies, Amarin Corporation, Fish products, Ethyl eicosapentaenoic acid, Blockbuster LLC, Chemistry, Economy of the United States

Based on that analysis, we determined that a commercialization team within Amarin and dedicated to VASCEPA is the best choice to maximize the blockbuster potential of the drug in Europe.

Key Points: 
  • Based on that analysis, we determined that a commercialization team within Amarin and dedicated to VASCEPA is the best choice to maximize the blockbuster potential of the drug in Europe.
  • We look forward to advancing VASCEPA through the regulatory process and maximizing the blockbuster potential of VASCEPA in Europe to help millions of patients in need.
  • Over the past year, Amarin has made considerable progress laying the foundation for a successful commercial launch in Europe.
  • To enable Amarin to deliver on its vision in Europe, the company announces its recent hiring of Karim Mikhail as senior vice president, commercial head Europe.

Global Hypertriglyceridemia Therapeutics Market to Generate Revenue of US$ 12,863.1 Million by end of 2027, Says Coherent Market Insights

Retrieved on: 
Monday, July 27, 2020
Biotechnology, General Health, Health, Pharmaceutical, Oncology, Fish products, Organic compounds, Amarin Corporation, Chemistry, Ethyl eicosapentaenoic acid, Hypertriglyceridemia, Triglyceride, Compound annual growth rate, Academic disciplines

According to Coherent Market Insights, the global hypertriglyceridemia therapeutics market is estimated to be valued at US$ 9,716.6 million in 2020 and is projected to exhibit a CAGR of 4.09% during the forecast period (2020-2027).

Key Points: 
  • According to Coherent Market Insights, the global hypertriglyceridemia therapeutics market is estimated to be valued at US$ 9,716.6 million in 2020 and is projected to exhibit a CAGR of 4.09% during the forecast period (2020-2027).
  • The global hypertriglyceridemia therapeutics market is expected to witness considerable growth owing to approvals of novel drugs for the treatment of hypertrigleridemia and related cardiovascular diseases.
  • For instance, in January 2020, Amarin Corporations VASCEPA was approved in Canada to minimize the risk of cardiovascular events.
  • The global hypertriglyceridemia therapeutics market is expected to register a CAGR of 4.09% during the forecast period (2020-2027) owing to the increasing focus of pharmaceutical companies on developing novel drugs for hypertriglyceridemia.